Member Info for Laura2022

The strategic rationale for Physiomics to develop the new Biostatistics services is three-fold. Firstly, the application of Modelling & Simulation and Biostatistics in drug development overlaps, with often the output of the former being a key input to the latter, allowing for natural follow-on work to be offered to clients. Secondly, biostatistics is a necessary component to the setup, conduct and reporting of any interventional clinical trial, from Phase 1 through to Phase 4, regardless of the therapeutic area. This opens a significant market for the Company, giving greater opportunity to scale. 

Https://www.londonstockexchange.com/news-article/PYC/new-services-launch-and-website-update/16694404

The volume and complexity of data that is generated by and accessible to the drug development industry is increasing significantly, driven in part by advancements in technology (i.e. omics technologies, data storage technologies etc.), complex trial design, real-world evidence and regulatory pressures.

The experience of the Physiomics team in routinely handling vast, complex data sets and ability to build model frameworks that can prioritise and visualise data from disparate public sources to align with your research objectives, allows extraction of unique insights that can inform your development/pipeline strategy.

Sienna

Please read the last RNSs

It's all there

The 3mln is my 4th buy

Great summary NK

Thanks for the link AndySmall

Bought my 2nd and 3rd amounts

Taken 1st lot of AGL

See my post last night and charts ..so oversold

Great to be in at 0.34p :)

Also think AGL will move

Certainly people looking silly now..eg aim123

Waiting for this other half of the TR1

33,592,352 (C.33mln)

Price or premiums

Not surprised

See my reply from last month when I emailed company /PS

They said bio stats one of the fastest growing markets globally

This new service line could make a material contribution to the Company's revenues and bottom line in the financial year ending 30 June 2025.

Dr Peter Sargent, CEO, commented: "We are delighted to have launched the new Biostatistics service line, as well as expand our Data Science and Bioinformatics Services. Not only can we now provide our clients a great breadth of services to support their drug development efforts, but these new services are an important component of the Company's growth strategy.

New Services Launch and Website Update

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the official launch of its Biostatistics offering and expansion of its Data Science and Bioinformatics services.

Leveraging its existing expertise and capabilities across the core Modelling and Simulation service line, the Company is moving forward to expand its offering into the synergistic service areas of Biostatistics and Data Science; both of which play crucial roles in drug development.

Biostatistics:

Biostatistics is an essential component of clinical research. It plays a pivotal role in the setup, conduct and reporting of all trials, regardless of therapeutic area, ensuring studies are well designed, data is accurately collected and analysed, and the results are interpreted correctly. For example, during the design of interventional trials, biostatistics is used to calculate the optimum number of patients to be recruited and help define what data should be collected so that the effect of the therapy can be detected, balancing this against the size and cost of the trial.

The strategic rationale for Physiomics to develop the new Biostatistics services is three-fold. Firstly, the application of Modelling & Simulation and Biostatistics in drug development overlaps, with often the output of the former being a key input to the latter, allowing for natural follow-on work to be offered to clients. Secondly, biostatistics is a necessary component to the setup, conduct and reporting of any interventional clinical trial, from Phase 1 through to Phase 4, regardless of the therapeutic area. This opens a significant market for the Company, giving greater opportunity to scale. Finally, with both service lines utilising the same business model and similar expertise across mathematics and data science, this allows the Company to operate flexible staffing across service lines to meet demand and maximise utilisation.

Aim123

Unlike BSFA which you were promoting and also SCE which you were until your U turn within 24hrs

PYC generated.record contracts won (£1.1mln) last year has order book grown to £1.7mln and cash half of the current £1.4mln cap and at centre of A.i in drug discovery

Please.go away

Aim123

Unlike BSFA which you were promoting and also SCE which you were until your U turn within 24hrs

PYC generated.record contracts won (£1.1mln) last year has order book grown to £1.7mln and cash half of the current £1.4mln cap and at centre of A.i in drug discovery

Please.go away

There's only been 1 tr1 , will take a few weeks for full story

A bad 2 weeks for Sneller

DELT SCE